- Home
- SHLS vs GHRS Comparison
SHLS vs GHRS Comparison
Compare SHLS & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHLS
- GHRS
- Stock Information
- Founded
- SHLS 1996
- GHRS 2018
- Country
- SHLS United States
- GHRS Ireland
- Employees
- SHLS N/A
- GHRS N/A
- Industry
- SHLS Semiconductors
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- SHLS Technology
- GHRS Health Care
- Exchange
- SHLS Nasdaq
- GHRS Nasdaq
- Market Cap
- SHLS 790.0M
- GHRS 753.0M
- IPO Year
- SHLS 2021
- GHRS 2021
- Fundamental
- Price
- SHLS $5.19
- GHRS $12.79
- Analyst Decision
- SHLS Buy
- GHRS Strong Buy
- Analyst Count
- SHLS 22
- GHRS 8
- Target Price
- SHLS $9.34
- GHRS $30.63
- AVG Volume (30 Days)
- SHLS 5.4M
- GHRS 427.1K
- Earning Date
- SHLS 08-05-2025
- GHRS 08-07-2025
- Dividend Yield
- SHLS N/A
- GHRS N/A
- EPS Growth
- SHLS N/A
- GHRS N/A
- EPS
- SHLS 0.12
- GHRS N/A
- Revenue
- SHLS $400,354,000.00
- GHRS N/A
- Revenue This Year
- SHLS $11.49
- GHRS N/A
- Revenue Next Year
- SHLS $11.71
- GHRS N/A
- P/E Ratio
- SHLS $43.45
- GHRS N/A
- Revenue Growth
- SHLS N/A
- GHRS N/A
- 52 Week Low
- SHLS $2.71
- GHRS $6.00
- 52 Week High
- SHLS $7.00
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- SHLS 51.08
- GHRS 44.21
- Support Level
- SHLS $4.45
- GHRS $11.32
- Resistance Level
- SHLS $5.01
- GHRS $13.16
- Average True Range (ATR)
- SHLS 0.42
- GHRS 0.88
- MACD
- SHLS -0.04
- GHRS -0.16
- Stochastic Oscillator
- SHLS 52.60
- GHRS 37.12
About SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.